ERBB2 and neoplasm: In the NSABP B-31 clinical trial, 174 patients with initially defined HER2 positive tumours but later found to be HER2 negative, were shown to have increased PFS and overall survival (OS) when treated with additional trastuzumab (82/174) compared to those not treated with trastuzumab (92/174) [5].